Literature DB >> 27038722

Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3).

Yuichi Chikata1, Hiroshi Iwata2, Eric A Osborn3, Kentaro Fukuda1, Iwao Okai1, Masayuki Shiozaki1, Yuki Kimura1, Kenji Inoue1, Yasumasa Fujiwara1, Masataka Sumiyoshi1.   

Abstract

Entities:  

Keywords:  CYP2C19 gene polymorphoisms; Critial stent thrombosis; Poor responder of clopidogrel

Mesh：

Substances：

Year:  2016        PMID： 27038722      PMCID： PMC4842144          DOI： 10.1016/j.ijcard.2016.03.067

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  10 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

3.  2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman
Journal:  J Am Coll Cardiol       Date:  2014-09-23       Impact factor: 24.094

4.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

5.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Authors:  Jessica L Mega; Willibald Hochholzer; Andrew L Frelinger; Michael J Kluk; Dominick J Angiolillo; Dean J Kereiakes; Steven Isserman; William J Rogers; Christian T Ruff; Charles Contant; Michael J Pencina; Benjamin M Scirica; Janina A Longtine; Alan D Michelson; Marc S Sabatine
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

6.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

7.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

8.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

Authors:  Jean-Philippe Collet; Thomas Cuisset; Grégoire Rangé; Guillaume Cayla; Simon Elhadad; Christophe Pouillot; Patrick Henry; Pascal Motreff; Didier Carrié; Ziad Boueri; Loic Belle; Eric Van Belle; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Olivier Barthélémy; Farzin Beygui; Johanne Silvain; Eric Vicaut; Gilles Montalescot
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

10.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875
  10 in total
  2 in total

1.  Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).

Authors:  Shuxia Chen; Yi Zhang; Lili Wang; Yanping Geng; Jian Gu; Qingqing Hao; Hua Wang; Peng Qi
Journal:  Med Sci Monit       Date:  2017-08-07

2.  Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles: A case report.

Authors:  Lanping Ding; Zhichun Gu; Rong Wang; Yichen Li; Yun Fang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.